Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × tucatinib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1 CNS 1 Breast 1

Conditions

Breast Neoplasms 1 Brain Neoplasms 1

Interventions

TIC10 compound 4 trametinib 2 selpercatinib 2 naxitamab 2 entrectinib 2 dabrafenib 2 Granulocyte-Macrophage Colony-Stimulating Factor 2 Crizotinib 2 AZD 6244 2 vorasidenib 1 tucatinib 1 tovorafenib 1 sacituzumab govitecan 1 mirdametinib 1 lutetium Lu 177 dotatate 1 copper dotatate CU-64 1 belzutifan 1 Vincristine 1 Trastuzumab 1 Lutetium-177 1 Lutetium 1 Eflornithine 1 Carboplatin 1 Capecitabine 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02614794 2023-08-14

HER2CLIMB

Seagen Inc.

Phase 2 Completed

612 enrolled 30 charts 2 FDA

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡